Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study

Skin Cancer

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

Eur J Cancer

Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS

doi: 10.1016/j.ejca.2024.113563

Skin Cancer

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

Eur J Cancer

Pires da Silva I, Li I, Ugurel S, Serra-Bellver P, Andhale A, Burnette H, Aya F, Conway JW, Braden J, Carlino MS, Menzies AM, Weichenthal M, Mohr P, Gutzmer R, Arance AM, Johnson DB, Lorigan P, Schadendorf D, Lo SN, Long GV

doi: 10.1016/j.ejca.2024.114101

Skin Cancer

Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

Eur J Cancer

Taylor AM, McKeown J, Dimitriou F, Jacques SK, Zimmer L, Allayous C, Yeoh HL, Haydon A, Ressler JM, Galea C, Woodford R, Kahler K, Hauschild A, Festino L, Hoeller C, Schwarze JK, Neyns B, Wicky A, Michielin O, Placzke J, Rutkowski P, Johnson DB, Lebbe C, Dummer R, Ascierto PA, Lo S, Long GV, Carlino MS, Menzies AM

doi: 10.1016/j.ejca.2024.113561

Skin Cancer

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

Eur J Cancer

Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L

doi: 10.1016/j.ejca.2024.113976

Skin Cancer

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome

Eur J Cancer

Jurlander RS, Guldbrandt LM, Holmstroem RB, Madsen K, Donia M, Haslund CA, Schmidt H, Bastholt L, Ruhlmann CH, Svane IM, Ellebaek E

doi: 10.1016/j.ejca.2024.115053

SPECIAL REPORT

Genitourinary Cancer

EAU Annual Congress 2024: adjuvant therapy for high-risk muscle-invasive urothelial carcinoma with PD-L1 expression ≥ 1

Lung, Respiratory and Thoracic Cancer

Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal

Lung Cancer

Chour A, Basse C, Lebossé F, Bonte PE, Girard N, Duruisseaux M

doi: 10.1016/j.lungcan.2024.107789

Skin Cancer

Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy

Eur J Cancer

Egeler M, Lai-Kwon J, Tissier R, Fraterman I, Kuijpers A, Van Houdt W, Wilgenhof S, Rao A, Sandhu S, Lee R, Eriksson H, van Leeuwen M, de Ligt K, van Akkooi A, van de Poll-Franse L

doi: 10.1016/j.ejca.2024.113601

Skin Cancer

Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study

Eur J Cancer

Petersen SK, Hansen CR, Ellebaek E, Schmidt H, Haslund CA, Ruhlmann CH, Bastholt L

doi: 10.1016/j.ejca.2024.114099

Related content

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome

EAU Annual Congress 2024: adjuvant therapy for high-risk muscle-invasive urothelial carcinoma with PD-L1 expression ≥ 1

Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal

Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy

Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study